291 related articles for article (PubMed ID: 30573406)
21. Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials.
Zheng W; Zhu XM; Zhang QE; Cai DB; Yang XH; Zhou YL; Ungvari GS; Ng CH; He SH; Peng XJ; Ning YP; Xiang YT
Schizophr Res; 2019 Jul; 209():12-21. PubMed ID: 31164254
[TBL] [Abstract][Full Text] [Related]
22. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
23. Adjunctive Fluvoxamine for Schizophrenia: A Meta-analysis of Randomized Double-Blind, Placebo-Controlled Trials.
Zheng W; Xiang YQ; Cai DB; Yang XH; Zhang L; Zheng W; Lu XB; Tong YM; Huang X; Ungvari GS; Sim K; Ning YP; Xiang YT
J Clin Psychopharmacol; 2020; 40(4):386-390. PubMed ID: 32618683
[TBL] [Abstract][Full Text] [Related]
24. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
[TBL] [Abstract][Full Text] [Related]
25. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
Josiassen RC; Joseph A; Kohegyi E; Stokes S; Dadvand M; Paing WW; Shaughnessy RA
Am J Psychiatry; 2005 Jan; 162(1):130-6. PubMed ID: 15625211
[TBL] [Abstract][Full Text] [Related]
26. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
[TBL] [Abstract][Full Text] [Related]
27. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Acceptability of Cariprazine in Acute Exacerbation of Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials.
Zhao MJ; Qin B; Wang JB; Zhang YP; Zhao JT; Mao YG; Zhang XY; Zhang RL
J Clin Psychopharmacol; 2018 Feb; 38(1):55-59. PubMed ID: 29257786
[TBL] [Abstract][Full Text] [Related]
29. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials.
Nitta M; Kishimoto T; Müller N; Weiser M; Davidson M; Kane JM; Correll CU
Schizophr Bull; 2013 Nov; 39(6):1230-41. PubMed ID: 23720576
[TBL] [Abstract][Full Text] [Related]
30. Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study.
Lee MR; Wehring HJ; McMahon RP; Linthicum J; Cascella N; Liu F; Bellack A; Buchanan RW; Strauss GP; Contoreggi C; Kelly DL
Schizophr Res; 2013 Apr; 145(1-3):110-5. PubMed ID: 23415472
[TBL] [Abstract][Full Text] [Related]
31. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.
Anil Yağcioğlu AE; Kivircik Akdede BB; Turgut TI; Tümüklü M; Yazici MK; Alptekin K; Ertuğrul A; Jayathilake K; Göğüş A; Tunca Z; Meltzer HY
J Clin Psychiatry; 2005 Jan; 66(1):63-72. PubMed ID: 15669890
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: a meta-analysis of double-blind randomized placebo-controlled trials.
Kishi T; Mukai T; Matsuda Y; Moriwaki M; Iwata N
J Psychiatr Res; 2013 Nov; 47(11):1557-63. PubMed ID: 23899496
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
34. No effect of adjunctive, repeated-dose intranasal insulin treatment on psychopathology and cognition in patients with schizophrenia.
Fan X; Liu E; Freudenreich O; Copeland P; Hayden D; Ghebremichael M; Cohen B; Ongur D; Goff DC; Henderson DC
J Clin Psychopharmacol; 2013 Apr; 33(2):226-30. PubMed ID: 23422397
[TBL] [Abstract][Full Text] [Related]
35. Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: A meta-analysis.
Bartoli F; Crocamo C; Di Brita C; Esposito G; Tabacchi TI; Verrengia E; Clerici M; Carrà G
J Psychiatr Res; 2019 Jan; 108():24-33. PubMed ID: 30447508
[TBL] [Abstract][Full Text] [Related]
36. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
[TBL] [Abstract][Full Text] [Related]
37. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.
Kane JM; Yang R; Youakim JM
Schizophr Res; 2012 Mar; 135(1-3):116-22. PubMed ID: 22178084
[TBL] [Abstract][Full Text] [Related]
38. Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Jiang WL; Cai DB; Yin F; Zhang L; Zhao XW; He J; Ng CH; Ungvari GS; Sim K; Hu ML; Zheng W; Xiang YT
Transl Psychiatry; 2020 Apr; 10(1):117. PubMed ID: 32327628
[TBL] [Abstract][Full Text] [Related]
39. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
[TBL] [Abstract][Full Text] [Related]
40. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
